Archive
231 releases
European launch of BelAgeAM, Inner7 and KroNuitPM combines fermented ingredients with convenient drink formats as wellness becomes an increasingly…
CS2009, an Innovative PD-1/VEGF/CTLA-4 trispecific antibody, demonstrates a differentiated profile through synergistic triple-pathway targeting,…
111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special…
Kansas City's historic West Bottoms serves up vintage treasures, friend-filled giveaways, frozen turkey bowling, free line dancing, and fireside fun…
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the…
- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical…
The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant…
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering,…
Dr. Thanapoom "Mo" Boonipat, plastic surgeon and founder of FacePlus Plastic Surgery Institute in Lubbock, led a hands-on suturing workshop and…
Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational…
Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO…
Celebrities, athletes and creators came together for an action-packed night of gaming, immersive entertainment and exclusive experiences on Cosm's…
Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of…
PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65;…
Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy…
JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between…
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and…
At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data…
The Oxnard restaurant transforms into a hauntingly festive destination with themed cocktails, spooky culinary creations, and immersive Halloween…
Brentwood-based Anchored Counseling Company is expanding professional education for area therapists. The team's training in compassionate…
